Régis Olivier

Régis brings more than 25 years of experience in the areas of finance, structuring and management of health technology companies. Prior to joining Tridek One, Regis was CEO of Axess Vision Technology, a company dedicated to the development of single-use medical endoscopes where he led the launch of new products and successfully completed new financing rounds. Also former CFO of Echosens, a medical technology company specializing in the non-invasive detection of liver disease, he completed the structuring and sale of the company in 2011. Previously, he held several positions as a financial analyst and financial controller in several industrial companies. Régis holds a Master degree in Management and Finance from EDC Paris.


Jorge Kirilovsky

Jorge is recognized as an international expert in the field of drug discovery. A former vice president and head of drug discovery center in France, Jorge led a group of more than 100 biologists, chemists, pharmacokinetists and clinicians working together to identify new drug candidates for development. The discovery of Tadalafil (Cialis™) for the treatment of erectile dysfunction and the first epigenetic drug to achieve clinical development are among the main contributions of his team. Dr Kirilovsky has also participated in the identification and selection of about twenty drug candidates in the fields of immuno-inflammation, cardiovascular diseases and oncology. Jorge is currently a member of the Health Expert Committee of BPI Large Ventures, the SATT Paris-Saclay Investment Committee and the Medicene Paris Project Appraisal Committee. In addition, he supports Yukin Therapeutics. Jorge Kirilovsky received his Ph.D. in biochemistry from the Hebrew University of Jerusalem and completed postdoctoral training in molecular neurobiology at the Institut Pasteur in Paris.


Antonino Nicoletti, Scientific Founder, Auditor

Professor of immunology, Deputy head at Insserm U1148, Hôpital Bichat, Paris.